Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma

Published:2017-05 Issue:5 Volume:12 Page:878-883
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Rangachari Deepa,VanderLaan Paul A.,Shea Meghan,Le Xiuning,Huberman Mark S.,Kobayashi Susumu S.,Costa Daniel B.

Funder

American Cancer Society

National Cancer Institute

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches;Shea;Ther Adv Respir Dis,2016

2. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

3. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

4. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

5. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer;VanderLaan;Lung Cancer,2014

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib;Targeted Oncology;2024-06-03

2. Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients;Thoracic Cancer;2024-03-08

3. PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center;Journal of the Egyptian National Cancer Institute;2024-01-29

4. Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024

5. Molecular pathology of non‐small cell carcinoma;Histopathology;2023-11-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3